ContraVir Pharmaceuticals to Present Three Posters at AASLD 2017 and Participate in the Search for HBV / HDV Cure Analyst Day...
October 12 2017 - 6:00AM
ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical
company focused on the development and commercialization of
targeted antiviral therapies, announced today it will participate
in an analyst day event sponsored by the Liver Institute and
Foundation for Education and Research (LIFER) titled, “The Search
for HBV / HDV Cure.” The event will take place on Friday, October
20, 2017, between 8-00am-2:00pm at the Ritz-Carlton, Pentagon City.
Invited attendees will include companies in HBV and HDV drug
development, research analysts and selected academics.
Dr. John-Sullivan-Bolyai, M.D., MPH, Chief Medical Officer and
Robert Foster, Pharm.D., Ph.D., Chief Scientific Officer of
ContraVir will be participating in two panel discussions with
colleagues discussing advances in HBV and HDV cure.
As previously announced, ContraVir will be presenting three
poster presentations the following day at AASLD, The Liver
Meeting®, in Washington, DC.
Poster #1: "Pharmacokinetics, Safety and
Antiviral Activity of Tenofovir exalidex (TXL), A Novel Prodrug of
Tenofovir, Administrated as Ascending Multiple Doses to
HBV-Infected Subjects: A 28 Day Study Final
Analyses"Publication Number: 943Date
and Time: October 21, 2017 from 2:00 PM to 7:30
PM Session: Hepatitis B: New and
Approved Treatment Location: Washington
Convention Center, Hall D
Poster #2:"Independent and Combinational
Anti-HBV Effects of CRV431 and TXL in the HBV Transgenic Mouse
Model"Publication
Number: 907 Date and
Time: October 21, 2017 from 2:00 PM to 7:30
PM Session: Hepatitis B: New and
Approved Treatment Location: Washington
Convention Center, Hall D
Poster #3:"CRV431 Blocks NTCP-Mediated Uptake
of HBV and HDV Independently of Effects on Bile Acid
Transport"Publication
Number: 928 Date and
Time: October 21, 2017 from 2:00 PM to 7:30
PM Session: Hepatitis B: New and
Approved Treatment Location: Washington
Convention Center, Hall D
ContraVir’s poster presentations from AASLD 2017 will be
available on the company’s website following their disclosure at
the meeting at
http://ir.contravir.com/events-and-presentations/presentations. For
further information about the 2017 AASLD meeting visit:
https://www.aasld.org/events-professional-development/liver-meeting.
About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the
development and commercialization of targeted antiviral therapies
with a specific focus on developing a potentially curative therapy
for hepatitis B virus (HBV). The Company is developing two novel
anti-HBV compounds with complementary mechanisms of action. TXL™
currently in Phase 2a, is designed to deliver high intrahepatic
concentrations of TFV, while minimizing off-target effects caused
by high levels of circulating TFV. CRV431, the other anti-HBV
compound, is a next-generation cyclophilin inhibitor with a unique
structure that increases its potency and selective index against
HBV. ContraVir is also developing Valnivudine™, an orally available
nucleoside analogue prodrug; Valnivudine™ is currently in Phase 3
for the treatment of herpes zoster. In addition to direct
antiviral activity, Phase 2 data suggest that Valnivudine™ has the
potential to reduce the incidence of debilitating
shingles-associated pain known as post-herpetic neuralgia
(PHN). For more information visit www.contravir.com.
Forward Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as "anticipate," "believe," "forecast,"
"estimated" and "intend," among others. These forward-looking
statements are based on ContraVir's current expectations and actual
results could differ materially. There are a number of factors that
could cause actual events to differ materially from those indicated
by such forward-looking statements. These factors include, but are
not limited to, substantial competition; our ability to continue as
a going concern; our need for additional financing; uncertainties
of patent protection and litigation; uncertainties with respect to
lengthy and expensive clinical trials, that results of earlier
studies and trials may not be predictive of future trial results;
uncertainties of government or third party payer reimbursement;
limited sales and marketing efforts and dependence upon third
parties; and risks related to failure to obtain FDA clearances or
approvals and noncompliance with FDA regulations. As with any drug
candidates under development, there are significant risks in the
development, regulatory approval, and commercialization of new
products. There are no guarantees that future clinical trials
discussed in this press release will be completed or successful, or
that any product will receive regulatory approval for any
indication or prove to be commercially successful. ContraVir does
not undertake an obligation to update or revise any forward-looking
statement. Investors should read the risk factors set forth in
ContraVir's Form 10-K for the year ended June 30, 2017 and other
periodic reports filed with the Securities and Exchange
Commission.
For further information, please contact:
Sharen Pyatetskaya Director of Investor Relations
sp@contravir.com; (732) 902-4028
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Apr 2023 to Apr 2024